The Fund selects Charlottesville-based ventures; Offers experiential learning course for MBA students Charlottesville, VA (January 17, 2018) – Since its launch, the UVA LVG Seed Fund has made three investments in companies based on technology dev...
By Jacob Demmitt [email protected] 381-8621 Dec 7, 2017 TearSolutions, a Charlottesville-based biotechnology startup just received an $8.5 million shot in the arm, courtesy of the VTC Innovation Fund and Pharmstandard International, one of ...
By: Cheryl Guttman Krader Ophthalmology Times Investigational agent represents a replacement therapy to correct tear deficiency A first-in-class topical synthetic peptide being developed as a treatment for dry eye disease (Lacripep, TearSolutions Inc...
By: Emily Dinning (Photo by Dan Addison, University Communications) UVA Today University of Virginia Health System researchers have developed a potential therapeutic treatment for dry eye, with human testing to start in March. The drug differs from o...
By Katie McNally (UVA Today) Despite spending billions of dollars annually on prescription and over-the-counter eye care products, millions of Americans suffer from chronic dry eye with few or no options for lasting relief. TearSolutions, a new Unive...
TearSolutions LLC, a Charlottesville-based biotechnology company, has successfully closed its $3M Series A round with investments led by Santen Pharmaceuticals, Medarva Innovations LLC, the Center for Innovative Technology, and Launch Capital. The fu...